AACR 2022: Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage SCLC

Adebrelimab (SHR-1316) is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine .

Patients with ES-SCLC without systemic therapy were randomized 1:1 to receive 4-6 cycles of treatment, one of which received Adebrelimab (20 mg/kg, intravenous, d1, q3w) + carboplatin (AUC 5 , d1, q3w) + etoposide (20mg/kg, intravenous, d1, q3w) treatment, the other group received placebo + carboplatin (AUC 5, d1, q3w) + etoposide (20mg/kg, intravenous injection, d1, q3w), followed by maintenance therapy with adebelimumab or placebo

462 patients were randomized and received treatment (230 in the Adebrelimab+chemotherapy group; 232 in the placebo+chemotherapy group)

As assessed by the Independent Review Committee (IRC), progression-free survival (PFS) was 5.

This study demonstrated that the addition of adebrelimab to chemotherapy significantly improved OS with an acceptable safety profile, and data from this trial support this combination regimen as a new first-line treatment option for ES-SCLC